Loading
A phase 2 trial of Trastuzumab in colorectal cancer, run by Suzhou Teligene Ltd., now recruiting.
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06589830 by Suzhou Teligene Ltd., with 80 participants planned, started 2025-05-13 and due to reach its primary completion in 2026-10. Interventions recorded: TL938 Capsules, Trastuzumab. Conditions listed: Colorectal Cancer Metastatic, Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-amplified colorectal cancer, Trastuzumab, Monoclonal antibodies.
Shares HER2-amplified colorectal cancer, Trastuzumab, Monoclonal antibodies.
Shares Trastuzumab, Monoclonal antibodies.
Shares Trastuzumab, Monoclonal antibodies.
Shares HER2-amplified colorectal cancer, Trastuzumab, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/